FARWANIYA HOSPITAL
🇰🇼Kuwait
Clinical Trials
5
Active:0
Completed:5
Trial Phases
3 Phases
Phase 2:2
Phase 4:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (40.0%)Phase 2
2 (40.0%)Phase 4
1 (20.0%)The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients
Phase 2
Completed
- Conditions
- Infectious KeratitisCorneal PerforationExposure Keratitis
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Farwaniya Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT06539663
- Locations
- 🇰🇼
Farwaniya Hospital, Kuwait, Kuwait
Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.
Not Applicable
Completed
- Conditions
- Management of Punctal Stenosis
- Interventions
- Device: mini-monoka stent
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Farwaniya Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05771012
- Locations
- 🇰🇼
Farwanyia Hospital, Al Farwānīyah, Farwanyia, Kuwait
Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis
Phase 4
Completed
- Conditions
- Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Farwaniya Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05720715
- Locations
- 🇰🇼
Farwanyia Hospital, Al Farwānīyah, Farwanyia, Kuwait
Omnigen in Acute Chemical Eye Injuries
Not Applicable
Completed
- Conditions
- Acute Chemical Eye Injuries
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Farwaniya Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05618522
- Locations
- 🇰🇼
Farwanyia Hospital, Al Farwānīyah, Farwanyia, Kuwait
Topical Cyclosporine-A for Management of Epiphora
Phase 2
Completed
- Conditions
- Epiphora
- Interventions
- Drug: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Farwaniya Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT04637633
- Locations
- 🇰🇼
Farwanyia Hospital, Kuwait, Farwanyia, Kuwait
News
No news found